Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + camrelizumab + chemotherapy for pancreatic cancer
ChiCTR2200064322Phase 4Not yet recruiting
- Sponsor
- Zhenjiang First People's Hospital
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of endostar and camrelizumab in pancreatic cancer (PC) (2 arms), sponsored by Zhenjiang First People's Hospital. Primary endpoint: Objective response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
endostarcamrelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200064322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064322.